Array Technologies enters the final week of September with short sellers holding firm, analysts cutting targets, and the borrow market at its tightest all year.
Short interest is the dominant story here. Bears hold 24.1% of the free float, a level that ranks in the 2nd percentile of the ORTEX universe, meaning almost no stock carries more concentrated short positioning. That figure rose 13% over the past month, jumping sharply in the second half of September after a mid-month drop. The most recent FINRA fortnightly settlement, covering the September 15 period, confirmed 35.3 million shares short with a days-to-cover ratio of 6.4, meaning shorts would need more than a week of average volume to exit. The ORTEX short score sits at 74.2, near the top of its recent range and consistent with a stock the model flags as heavily shorted and technically challenged.
The borrow market reinforces how entrenched that positioning has become. Availability has fallen to zero: every share in the lending pool is currently lent out, matching the tightest reading of the past 52 weeks. That has pushed cost to borrow to 1.12%, up 26% on the week and 45% over the past month. These are not extreme absolute rates, but the direction is clear. Availability was still running above 9% in mid-September, and the collapse since then tracks the surge in short interest that began around September 10. Anyone adding new shorts now does so with no buffer in the lending pool.
Options, however, tell a more relaxed story. The put/call ratio is 0.20, close to its 52-week low of 0.16 and well below the 20-day average of 0.25. That divergence from the short-interest picture is notable: the lending market is stretched, but options traders are not paying up for downside protection. Wednesday September 28 saw the PCR spike briefly to 0.78, the sole outlier in an otherwise consistently low-put regime, suggesting that session's put activity was transient rather than a shift in positioning.
The Street moved quickly this week to reset expectations. Jefferies reinstated coverage with a Buy rating and a $7.00 target on September 29, the lone constructive voice in a cluster of cuts. Piper Sandler the following day trimmed its target to $4.00 from $5.00 while keeping a Neutral rating, putting it just a cent above the current price of $3.99. UBS downgraded to Neutral from Buy on September 18, cutting its target from $10.00 to $5.00. The mean analyst target across the board is $8.49, more than twice the current price, but that gap largely reflects stale pre-downgrade estimates rather than fresh conviction. The recent direction of travel on the Street is uniformly lower. Bears point to demand softening for solar equipment, margin dilution from international expansion, and Array's limited direct relationships with end customers. Bulls, as the Jefferies reinstatement signals, see the stock as oversold after a steep year-to-date decline, with forward earnings growth optically strong.
On valuation, the stock trades at 4.7x trailing earnings and 6.4x EV/EBITDA. The EPS earnings surprise factor scores in the 17th percentile, a weak track record against consensus, while the 12-month forward earnings growth estimate ranks in the 66th percentile. Price-to-book is negative, reflecting accumulated losses on the balance sheet. Institutionally, BlackRock holds nearly 19% of shares as the dominant passive anchor, while GMO lifted its stake by 1.1 million shares to 7.7% as of June 30. UBS Asset Management added 3.6 million shares as of July 31, the largest recent addition among the top holders.
On the insider front, the September 24 activity is best read as a compensation event rather than a signal of conviction. The CEO, COO, Chief Accounting Officer and Chief Human Resources Officer all exercised grants (transaction code M) and immediately surrendered shares to cover tax withholding (code F). No open-market purchases appear in the recent filings. The net insider share count over 90 days is flat.
Earnings history carries a warning. The August 5 print produced a one-day move of negative 12.6% and the stock was still down 13.6% five days later. The next event is scheduled for November 5. Between now and then, the question is whether the lending market, already at maximum tightness, creates any friction for continued short-building, or whether the zero-availability reading simply holds as an equilibrium while the stock trades near multi-year lows.
See the live data behind this article on ORTEX.
Open ARRY on ORTEX →ORTEX Market Intelligence content is generated by AI from a snapshot of ORTEX's proprietary data. Content is informational only and does not constitute investment advice.
